A national drug policy advocacy organization is condemning how a prominent psychedelic research body responded to a B.C. woman’s allegations of sexual and physical abuse during clinical trials for MDMA-assisted psychotherapy.
Concerns about patient safety, reports of increased suicidal thinking and allegations of flawed research are at the heart of a new complaint to Health Canada over the much-hyped clinical trials for the use of MDMA to treat post-traumatic stress disorder.